Ganirelix
A GnRH antagonist used to prevent premature LH surges in assisted reproduction.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GnRH antagonist used to prevent premature LH surges in assisted reproduction.
FDA-approved to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation.
Its effect depends on protocol timing and clinical context, not general hormone optimization.
Why It's Being Studied
- Controlled ovarian stimulation
- LH suppression
Mechanism of Action
Pituitary GnRH-receptor antagonism suppresses LH release during controlled ovarian stimulation.
Pituitary GnRH-receptor antagonism suppresses LH release during controlled ovarian stimulation. Its effect depends on protocol timing and clinical context, not general hormone optimization.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Controlled ovarian stimulation
- LH suppression
- Subcutaneous approved medicine
Evidence Summary
Clinical studies support the defined fertility-protocol role, not independent improvement of every fertility outcome.
Higher tiers carry more weight. Filled tiers have evidence for Ganirelix; tap to read it.
- Clinical studies support the defined fertility-protocol role, not independent improvement of every fertility outcome.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical studies support the defined fertility-protocol role, not independent improvement of every fertility outcome.
Reported Adverse Events in Research
- Hypersensitivity and injection reactions are possible; ovarian hyperstimulation relates to the broader regimen.
Limitations of Current Evidence
- Its effect depends on protocol timing and clinical context, not general hormone optimization.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Ganirelix | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Ganirelix — prescribing label